Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB1 | P08183 | 1/20 | 0.51 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.38 |
| ▸ | EED | O75530 | 1/20 | 0.38 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.38 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.38 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.38 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.37 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.36 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.36 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29684478 | 0.96 | ABCB1 (0.52) | ABCB1UTS2REEDRBBP4SUZ12 | |
| SCHEMBL669374 | 0.96 | ABCB1 (0.52) | ABCB1UTS2REEDRBBP4SUZ12 | |
| SCHEMBL3766257 | 0.94 | ABCB1 (0.60) | ABCB1 | |
| SCHEMBL2681921 | 0.93 | ABCB1 (0.54) | ABCB1UTS2REEDRBBP4SUZ12 | |
| SCHEMBL29684814 | 0.93 | ABCB1 (0.54) | ABCB1UTS2REEDRBBP4SUZ12 | |
| SCHEMBL667855 | 0.93 | ABCB1 (0.54) | ABCB1UTS2REEDRBBP4SUZ12 | |
| SCHEMBL29727267 | 0.90 | ABCB1 (0.62) | ABCB1UTS2R | |
| SCHEMBL668804 | 0.90 | ABCB1 (0.62) | ABCB1UTS2R | |
| SCHEMBL668210 | 0.89 | ABCB1 (0.56) | ABCB1UTS2REEDRBBP4SUZ12 | |
| SCHEMBL29684844 | 0.89 | ABCB1 (0.56) | ABCB1UTS2REEDRBBP4SUZ12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9272986-B2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORPORATION (US) | 2016-03-01 | — | — | US | claimed |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | INTREXON CORP (US) | 2015-01-01 | — | — | US | claimed |
| EP-2455375-B1 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORP (US) | 2014-11-19 | — | — | EP | claimed |
| EP-2455375-A2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-05-23 | — | — | EP | claimed |
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-09-04 | — | — | US | claimed |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | HORMANN ROBERT EUGENE | 2008-08-14 | — | — | US | claimed |
| EP-1603860-A4 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | INTREXON CORP (US) | 2008-05-14 | — | — | EP | claimed |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | HORMANN ROBERT E | 2008-05-01 | — | — | US | claimed |
| US-7304161-B2 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | INTREXON CORPORATION (US) | 2007-12-04 | — | — | US | claimed |
| EP-1603860-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RheoGene Holdings Inc. (US) | 2005-12-14 | — | — | EP | claimed |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | ROHM AND HAAS COMPANY | 2005-09-22 | — | — | US | claimed |
| WO-2004072254-A2 | DIACYLHYDRAZINE LIGANDS FOR MODULATING THE EXPRESSION OF EXOGENOUS GENES IN MAMMALIAN SYSTEMS VIA AN ECDYSONE RECEPTOR COMPLEX | RHEOGENE HOLDINGS, INC (US) | 2004-08-26 | — | — | WO | claimed |
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-09-28 | — | — | US | disclosed |
| US-9677055-B2 | Modified forms of Pseudomonas exotoxin A | INTERXON CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20170037386-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2017-02-09 | — | — | US | disclosed |
| EP-2455375-B1 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | INTREXON CORP (US) | 2014-11-19 | — | — | EP | disclosed |
| WO-2013036574-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | INTREXON CORPORATION (US) | 2013-03-14 | — | — | WO | disclosed |
| EP-2455375-A2 | Diacylhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex | Intrexon Corporation (US) | 2012-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214627-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | ABCB1 2143/4885UTS2R 666/4885EED 1340/4885 |
| US-20170275600-A1 | MODIFIED FORMS OF PSEUDOMONAS EXOTOXIN A | CD4, CD47, CD14 | ABCB1 2448/4885UTS2R 2622/4885EED 992/4885 |
| US-20080194521-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; side effect reduction; genetic engineering | NR5A2, NR5A1, DECR1 | ABCB1 2143/4885UTS2R 666/4885EED 1340/4885 |
| US-20150005256-A1 | Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes in Mammalian Systems via an Ecdysone Receptor Complex | NR2E3, NR2C2, NR5A2 | ABCB1 2844/4885UTS2R 215/4885EED 1285/4885 |
| US-20080103113-A1 | Reduced level of background gene expression; responds to submicromolar concentrations of nonsteroidal ligand | NR5A1, NR0B2, NR0B1 | ABCB1 3211/4885UTS2R 623/4885EED 1952/4885 |
| US-20050209283-A1 | 3,5-Dimethyl-benzoic acid N-tert-butyl-N'-(3-hydroxymethyl-5-methyl-2,3-dihydro-benzo[1,4]dioxine-6-carbonyl)-hydrazide; 3,5-Dimethyl-benzoic acid N-(1-tert-butyl-2-cyano-vinyl)-N'-(3-methoxy-2-methylbenzoyl)-hydrazide | NR5A2, NR2C2, NR0B2 | ABCB1 2789/4885UTS2R 716/4885EED 1193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.